Phathom Pharmaceuticals Publishes Positive Data on VOQUEZNA in The American Journal of Gastroenterology
PRINCETON, NJ – May 16, 2024 – Phathom Pharmaceuticals, Inc. today announced the publication of data from a Phase 3 clinical trial of VOQUEZNA (vonoprazan fumarate) in The American Journal of Gastroenterology. The publication details results demonstrating significant improvements in healing rates and symptom relief for patients with erosive esophagitis (EE) and heartburn associated with gastroesophageal reflux disease (GERD).
VOQUEZNA, a potassium-competitive acid blocker (P-CAB), was approved by the FDA in November 2022 for the treatment of EE and provides rapid and sustained acid suppression. The published data further supports VOQUEZNA’s potential to address the significant unmet need for new GERD treatment options. the trial evaluated the efficacy of VOQUEZNA compared to lansoprazole in patients with EE, showing statistically significant improvements in both mucosal healing and symptom resolution.
Phathom Pharmaceuticals cautions that forward-looking statements contained within the press release regarding VOQUEZNA’s clinical profile,patient populations,business strategy,and future performance are subject to risks and uncertainties. These factors could cause actual results to differ materially from expectations,including potential setbacks in market acceptance or unexpected adverse side effects. Further details on these risks are available in Phathom’s filings with the Securities and Exchange commission (SEC).
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
Investor contact:
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA and Phathom Pharmaceuticals are registered trademarks of Phathom Pharmaceuticals, Inc.